{
    "clinical_study": {
        "@rank": "31735", 
        "arm_group": {
            "arm_group_label": "Sevacizumab", 
            "arm_group_type": "Experimental", 
            "description": "2mg/kg\u30015mg/kg\u30017.5mg/kg\u300110mg/kg\u300112.5mg/kg\u3001or 15mg/kg. d1, d29, d43, d57"
        }, 
        "brief_summary": {
            "textblock": "This study is to assess the safety, tolerability and pharmacokinetics of single dose and\n      multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with\n      advanced or metastatic solid tumors. The secondary objective is to explore the preliminary\n      anti-tumor effects."
        }, 
        "brief_title": "A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Tumors", 
            "Metastatic Solid Tumors"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed advanced or metastatic malignant solid\n             tumors;\n\n          -  Patients failed the standard anti-tumor therapy or don't have standard regimen;\n\n          -  At least one measurable lesion;\n\n          -  At least 4 weeks from the last chemotherapy, 6 weeks from mitomycin, and nitrosourea\n             treatment. If patients received anti-tumor biological products, at least four t1/2 of\n             washout period is needed;\n\n          -  Toxicity from previous treatment has to restore to \u2264 grade 1 (NCI CTC4.0);\n\n          -  ECOG performance status 0-1;\n\n          -  Life expectancy \u2265 3 months;\n\n          -  Adequate hematologic function: ANC \u2265 1.5 \u00d7 10^9 /L, HB \u2265 90 g /L (blood transfusion\n             allowed), PLT \u2265 100 \u00d7 10^9 /L;\n\n          -  Adequate hepatic function: ALT \u2264 2.5 \u00d7 ULN, AST \u2264 2.5 \u00d7 ULN, TBIL \u2264 1.5 \u00d7 ULN\n             (patients with liver metastases ALT \u2264 5 \u00d7 ULN, AST \u2264 5 \u00d7 ULN, TBIL \u2264 3 \u00d7 ULN);\n\n          -  Adequate renal function: creatinine \u2264 1 \u00d7 ULN;\n\n          -  Coagulation function: INR \u2264 1.5 \u00d7 ULN, APTT \u2264 1.5 \u00d7 ULN;\n\n          -  Patients of childbearing potential (male and female) must agree to use reliable\n             methods of contraception until at least 12 weeks after the last dose.\n\n        Exclusion Criteria:\n\n          -  HCV, TP or HIV antibody positive;\n\n          -  Previously received anti-VEGF protein drugs, such as bevacizumab;\n\n          -  Histologically proven squamous cell lung cancer or squamous cell carcinoma of the\n             head and neck;\n\n          -  Active hepatitis B infection;\n\n          -  Evidence of serious infection;\n\n          -  Symptomatic brain metastases;\n\n          -  Patients with proteinuria at screening (urine protein \u2265 1+);\n\n          -  History of abdominal fistula, gastrointestinal perforation, abdominal abscess within\n             6 months prior to enrollment;\n\n          -  Serious non-healing wounds, ulcers or fractures;\n\n          -  Major surgery (excluding biopsy) or significant trauma within 4 weeks prior to\n             enrollment;\n\n          -  Active bleeding within 3 months prior to enrollment;\n\n          -  Bleeding diathesis or coagulation disorder;\n\n          -  History of arterial or venous thrombosis;\n\n          -  History of myocardial infarction or stroke within 6 months prior to enrollment;\n\n          -  Unstable angina, congestive heart failure, New York Heart Association (NYHA) class II\n             heart failure, uncontrollable arrhythmia, uncontrolled hypertension (systolic blood\n             pressure> 150 mmHg and/or diastolic blood pressure> 100 mmHg);\n\n          -  Pregnant and lactating women;\n\n          -  Known allergies to any excipient in the study drug;\n\n          -  Patients with alcohol or drug dependence;\n\n          -  Participation in other clinical trials within 4 weeks before enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847118", 
            "org_study_id": "SIM-63-001"
        }, 
        "intervention": {
            "arm_group_label": "Sevacizumab", 
            "intervention_name": "Sevacizumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "contact": {
                "last_name": "Jin Li, MD, PhD", 
                "phone": "86-021-61733905"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China"
                }, 
                "name": "Fudan University Shanghai Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors", 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Jin Li, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847118"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57"
            }, 
            {
                "measure": "tmax", 
                "safety_issue": "No", 
                "time_frame": "d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57"
            }, 
            {
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57"
            }, 
            {
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57"
            }, 
            {
                "measure": "Objective Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "d29, d86"
            }, 
            {
                "measure": "Disease Control Rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "d29, d86"
            }
        ], 
        "source": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}